Back to the Traditional: Anti-COX Drugs Can Improve the Outcome of COVID-19 Patients Admitted to ICU
NCT ID: NCT04757792
Last Updated: 2021-02-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
475 participants
OBSERVATIONAL
2020-06-06
2021-02-11
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy of Addition of Naproxen in the Treatment of Critically Ill Patients Hospitalized for COVID-19 Infection
NCT04325633
Inhaled Ibuprofen to Treat COVID-19
NCT04382768
Comparison of the Efficacy of Paracetamol and Ibuprofen in the Management of Fever in Sepsis Patients
NCT06061575
Role of Ibuprofen and Other Medicines on Severity of Coronavirus Disease 2019
NCT04383899
A Prospective Study of Pattern of Chronic Use of NSAIDS in Patients Admitted to Emergency Department in Alexandria Main University Hospital.
NCT06816550
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
No NSAID
included patients who did not receive NSAID prior to having COVID-19 disease
File inquiry
Data extraction out of file registry
Apsirin
included patients who received acetylsalicylic acid (ASA) prior to having COVID-19 disease
File inquiry
Data extraction out of file registry
Celecoxib
included patients who received celecoxib (CEL) prior to having COVID-19 disease
File inquiry
Data extraction out of file registry
Miscellaneous
included patients who received miscellaneous NSAID other than ASA or CEL prior to having COVID-19 disease
File inquiry
Data extraction out of file registry
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
File inquiry
Data extraction out of file registry
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tanta University
OTHER
Cairo University
OTHER
Benha University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Adel F. Alkholy
Professor of Medical Biochemistry
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Adel Alkholy, Prof
Role: PRINCIPAL_INVESTIGATOR
Faculty of medicine, Banha University, Egypt
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Faculty of Medicine
Banhā, Qalyubia Governorate, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RC1-2-2021
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.